Trial · NCT07908797
Probiotic Trial for URTI Prevention in Healthy Adults
NCT07908797, Not applicable, Recruiting, Harokopio University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Probiotic Trial for URTI Prevention in Healthy Adults. Trials, record NCT07908797. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908797
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Probiotic Trial for URTI Prevention in Healthy Adults
- NCT number
- NCT07908797
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 140 participants, estimated
- Lead sponsor
- Harokopio University
- Conditions
- Upper Respiratory Tract Infections
- Interventions
- Probiotic Formula, Matching placebo
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of clinically confirmed upper respiratory tract infection (URTI) episodes per participant | 16 weeks (Week 0 to Week 16) | The number of clinically confirmed URTI episodes experienced by each participant during the study. |
| Secondary | Proportion of participants experiencing clinically confirmed URTI episodes | 16 weeks (Week 0 to Week 16) | Proportion of participants experiencing at least 1, at least 2, and at least 3 clinically confirmed URTI episodes during the study period. |
| Secondary | URTI episode duration and timing | 16 weeks (Week 0 to Week 16) | Duration of individual clinically confirmed URTI episodes, cumulative symptomatic days, URTI-free time, and time to first clinically confirmed URTI episode. |
| Secondary | Predominant symptom-based URTI clinical presentation | 16 weeks (Week 0 to Week 16) | Clinical characteristics and treatment outcomes of clinician-confirmed URTI episodes classified according to the prespecified study-specific symptom-domain classification. |
| Secondary | Sore-throat outcomes during clinically confirmed URTI episodes | 16 weeks (Week 0 to Week 16) | Number of clinically confirmed URTI episodes involving sore throat, duration and severity. |
| Secondary | Medication and healthcare utilisation related to URTI episodes | 16 weeks (Week 0 to Week 16) | Use of symptomatic medications, prescribed antibiotics, and healthcare services related to clinically confirmed URTI episodes. |
| Secondary | Days absent from work or study due to URTI illness | 16 weeks (Week 0 to Week 16) | Number of days absent from work or study because of clinically confirmed URTI illness during the study period. |
| Secondary | Health-related quality of life | Baseline (Week 0), Week 12, and Week 16 | Health-related quality of life assessed using the EQ-5D-5L at prespecified study timepoints. |
| Secondary | Gastrointestinal symptoms | Baseline (Week 0), Week 12, and Week 16 | Gastrointestinal symptom burden assessed using the 15-item Gastrointestinal Symptom Rating Scale (GSRS). |
| Secondary | Change in oral microbiota composition | Baseline (Week 0) to Week 12 | Changes in oral microbiota composition and prespecified microbiota features assessed using 16S rRNA gene sequencing of saliva samples collected at baseline and Week 12. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908797
GET https://conductscience.org/api/trials/v1/NCT07908797/registered